Drug ABBV-CLS-484 for advanced cancers that lack options
Part of Cancer, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You weigh at least 35 kg (about 77 lb).
- You’re expected to live at least 12 weeks, and you can manage daily activities at a moderate level.
- Your trial team needs blood test results that meet the study’s protocol limits.
- Your heart testing must be safe: the corrected QT time is below 470 ms, and there are no concerning ECG findings.
- You need measurable cancer on scans (measurable disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program provides access to an investigational drug for people who have already been part of the main clinical trial and have no other treatment options. It aims to give continued treatment when regular access is not possible.
This trial tests a new drug called AVA6103 for people with certain advanced solid tumors that have not responded to standard treatments. The drug may help by targeting a protein on cancer cells and interfering with their ability to multiply.
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
This study tests a new drug called ABBV-1480 combined with chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see if it works as well as or better than the current standard treatment, pembrolizumab (also known as Keytruda) with chemotherapy.
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
This trial tests an experimental drug called VBC108 in people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and effective.
Hear when a new Advanced Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.